NASD · US Equities - Industry Sector · USA
The companies inside FMED trade 86% above what we estimate they are worth. We could give a verdict on 69% of the fund's weight: 70 holdings as reported to the SEC at 31 May 2026.
Where the money is: 4% in companies in the buy zone, 5% about fairly valued, 60% overvalued, 31% without a verdict.
The ten largest holdings, with our verdict on each:
Its expense ratio is 0.50% a year: on $10,000 held flat that is $500 over 10 years and $1,000 over 20.